Hypoglycemia News and Research

RSS

Hypoglycemia, also called low blood glucose or low blood sugar, occurs when blood glucose drops below normal levels. Glucose, an important source of energy for the body, comes from food. Carbohydrates are the main dietary source of glucose.

Researchers design a more comfortable, reliable glucose monitor for people with diabetes

A more comfortable and reliable blood-sugar monitoring system is being designed by researchers in Sweden for people with diabetes. After successfully testing a prototype of a microneedle patch on a human subject, the completion of a system for clinical tests is now underway.

3 Jan 2019

Study shows how a novel regulatory mechanism serves as key biomarker for diabetes

A recent study led by researchers in Texas A&M University's department of nutrition and food science shows how a novel regulatory mechanism serves as an important biomarker for the development of diabetes, as well as a potential therapeutic target for its prevention.

20 Dec 2018

Eisai enters into agreement with Eurofarma for its anti-obesity agent lorcaserin

Eisai Co., Ltd. has entered into an agreement to grant exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride in Brazil to Eurofarma Laboratorios S.A. Under this agreement, Eisai will supply Eurofarma with lorcaserin. Eisai will receive a one-time contractual payment and is eligible for milestone payments for sales in Brazil.

17 Dec 2018

Study: Some people with Type 2 diabetes may be testing their blood sugar more often than needed

For people with Type 2 diabetes, the task of testing their blood sugar with a fingertip prick and a drop of blood on a special strip of paper becomes part of everyday life.

11 Dec 2018

Fasting for blood test can lead to hypoglycemia in patients who take diabetes medications

Fasting before getting your blood drawn for cholesterol tests is common practice, but new research from Michigan State University shows it is a contributing factor of low blood sugar, or hypoglycemia, in patients who take diabetes medications.

5 Dec 2018

Study highlights prevalence of regional disparities in the treatment of type 1 diabetes

How the autoimmune disease type 1 diabetes is treated also depends on where the patients live in Germany.

29 Nov 2018

New glucose binding molecule could be key to better metabolic control for diabetics

Scientists from the University of Bristol have designed a new synthetic glucose binding molecule platform that brings us one step closer to the development of the world's first glucose-responsive insulin which, say researchers, will transform the treatment of diabetes.

19 Nov 2018

Study identifies novel missense mutation affecting YARS causes multisystem disease

Researchers have identified a novel missense mutation in tyrosyl-tRNA synthetase (YARS c.499C>A, p.Pro167Thr) that causes a severe recessive disorder in affected individuals.

7 Nov 2018

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.

1 Nov 2018

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes - one of the nation's fastest growing chronic diseases.

17 Oct 2018

Eisai enters into agreement with Eurofarma for development and sales of lorcaserin in 17 countries

Eisai Co., Ltd. has entered into an agreement to grant exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride (generic name, product name in the United States: BELVIQ, product name for once-daily formulation in the United States: BELVIQ XR, "lorcaserin") in 17 countries in Latin America and the Caribbean, excluding Brazil, to Eurofarma Laboratorios S.A. which has a business foundation in Latin America.

16 Oct 2018

Extension trial assesses benefit of switching from flash monitoring to RT-CGM for hypoglycemia

In follow-up to the I HART CGM study, which showed the benefit of real-time continuous glucose monitoring compared to flash monitoring for time spent in hypoglycemia among adults with type 1 diabetes at high hypoglycemia risk, researchers conducted an extension trial that assessed the effects of continuing RT-CGM or switching from flash to RT-CGM of the subsequent 8 weeks.

15 Oct 2018

New report reveals concerning inadequacies in care for diabetes inpatients

Diabetes UK’s ‘Making Hospitals Safe for People with Diabetes’ report, released today (08/10/2018), has revealed concerning inadequacies in care for diabetes inpatients.

9 Oct 2018

Appetite-suppressant drug reduces diabetes risk and increases remission rates of blood sugar

New research presented at this year's annual meeting of the European Association for the Study of Diabetes in Berlin, Germany, and published in The Lancet, shows that the appetite-suppressant drug lorcaserin decreases risk of developing diabetes and increases the rates of remission of high blood sugar.

4 Oct 2018

Weight loss drug reduces risk of diabetes in patients with pre-diabetes, finds study

At the 2018 Meeting of the European Association for the Study of Diabetes, Brigham and Women's Hospital investigators from the Thrombolysis in Myocardial Infarction Study Group presented diabetes-related findings from CAMELLIA-TIMI 61, a clinical trial of overweight and obese patients designed to test lorcaserin, a weight loss drug manufactured by the trial's sponsor, Eisai Inc.

4 Oct 2018

Closed-loop insulin delivery improves blood sugar control in type 1 diabetes

A study has shown that hybrid day-night closed-loop insulin delivery systems are the most effective way of controlling blood sugar levels in type 1 diabetes.

3 Oct 2018

Closed-loop insulin delivery system shows better results for blood sugar control in type 1 diabetes

New research presented at this year's annual meeting of the European Association for the Study of Diabetes in Berlin, Germany, and published in The Lancet, shows that use of a hybrid day-night closed-loop insulin delivery system is better than sensor-augmented pump therapy for blood sugar control in poorly controlled type 1 diabetes.

3 Oct 2018

Study reveals connection between hunger and mood

It seems "hangry" isn't just a made-up term. University of Guelph researchers have revealed that the sudden drop in glucose we experience when we are hungry can impact our mood.

25 Sep 2018

One in five diabetes inpatients experienced hypoglycemia during hospital stay

Diabetes UK is urging healthcare professionals to be hypo-aware for Hypo-awareness Week (24th- 30th September). The charity wants to raise awareness about hypoglycemia and is encouraging healthcare professionals working in hospitals to look out for the signs of hypoglycemia and ensure those at high risk are given the necessary support.

25 Sep 2018

IQWiG recommends update in health care aspects of DMP ‘type 1 diabetes’

Disease management programmes should be regularly updated to adapt them to the current state of medical knowledge.

25 Sep 2018

Hypoglycemia News and Research

Further Reading

Researchers design a more comfortable, reliable glucose monitor for people with diabetes

Study shows how a novel regulatory mechanism serves as key biomarker for diabetes

Eisai enters into agreement with Eurofarma for its anti-obesity agent lorcaserin

Study: Some people with Type 2 diabetes may be testing their blood sugar more often than needed

Fasting for blood test can lead to hypoglycemia in patients who take diabetes medications

Study highlights prevalence of regional disparities in the treatment of type 1 diabetes

New glucose binding molecule could be key to better metabolic control for diabetics

Study identifies novel missense mutation affecting YARS causes multisystem disease

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

Eisai enters into agreement with Eurofarma for development and sales of lorcaserin in 17 countries

Extension trial assesses benefit of switching from flash monitoring to RT-CGM for hypoglycemia

New report reveals concerning inadequacies in care for diabetes inpatients

Appetite-suppressant drug reduces diabetes risk and increases remission rates of blood sugar

Weight loss drug reduces risk of diabetes in patients with pre-diabetes, finds study

Closed-loop insulin delivery improves blood sugar control in type 1 diabetes

Closed-loop insulin delivery system shows better results for blood sugar control in type 1 diabetes

Study reveals connection between hunger and mood

One in five diabetes inpatients experienced hypoglycemia during hospital stay

IQWiG recommends update in health care aspects of DMP ‘type 1 diabetes’

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News